Choice of starting dose and escalation for phase I studies of antitumor agents

This publication has 10 references indexed in Scilit:

• Response rates, duration of response, and dose response effects in phase I studies of antineoplastics
  Investigational New Drugs, 1991
• Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development
  JNCI Journal of the National Cancer Institute, 1990
• Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials
  JNCI Journal of the National Cancer Institute, 1990
• Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines
  European Journal of Cancer and Clinical Oncology, 1987
• Potential roles for preclinical pharmacology in phase I clinical trials.
  1986
• ANIMAL TOXICOLOGY FOR EARLY CLINICAL-TRIALS WITH ANTI-CANCER AGENTS
  1981
• Mouse and large-animal toxicology studies of twelve antitumor agents: Relevance to starting dose for Phase I clinical trials
  Cancer Chemotherapy and Pharmacology, 1979
• ADEQUACIES AND INADEQUACIES IN ASSESSING MURINE TOXICITY DATA WITH ANTI-NEOPLASTIC AGENTS
  1979
• Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
  1975
• Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology.
  1973